Radiopharm Theranostics Ltd has released a press release.
Strategic Co-Development Partnership with Lantheus for Aus
Filed with ASX ·
6ix hasn’t read this filing yet.
Radiopharm Theranostics Limited on 6ix
Earlier from Radiopharm Theranostics
- RAD 202 receives approval to start Phase 1 therapeutic trial
- Response to ASX Aware Letter
- Completion of preclinical data package for RAD 402
- Approval received to expand RAD204 Phase 1 trial
- RAD 301 shows strong imaging potential in pancreatic cancer
Later from Radiopharm Theranostics
- Lantheus increases shareholding in RAD with A$8m placement
- Clinical trial data shows RAD 101 detects Brain Metastases
- Half Year Report and Appendix 4D 31 December 2024
- New RAD202 data confirms positive tumor uptake
- First patient dosed in Phase IIb imaging for Brain Mets
Follow Radiopharm Theranostics into a list and get an email when it puts out news.
Follow Radiopharm Theranostics